DynamX

Dynamix Pharmaceuticals was a venture-backed biopharmaceutical company focused on the discovery and development of novel, targeted small molecule drugs for cancer and autoimmune disorders. The company utilized its proprietary in silico structure-based technology, DynamixFit™, to identify novel chemical entities that modulate the activity of flexible protein targets, such as kinases. Its pipeline primarily explored two therapeutic routes: intervening with cancer cell metabolism and selectively targeting cellular signaling pathways via Type II kinase inhibitors. Headquartered in Rehovot, Israel, the company aimed to significantly shorten drug development times and lower R&D costs through its integrated discovery engine. However, the company is currently listed as out of business.